Thursday, August 5, 2021 Daily Archives

Thermo: Cell & gene therapy key to further growth in 2021

by

Thermo Fisher Scientific says cell and gene therapy contracting, PPD and ongoing CAPEX investments will drive growth. The tech and services firm outlined its plans during a Q2 call, explaining its belief that the cell and gene therapy sector prompted its recent investment in a manufacturing center at the University of California San Francisco. CEO Mark Casper predicted the partnership would “will lead to new capabilities for our customers and ultimately better outcomes for patients.†He added a desire to…

August 5, 2021

Bayer buys Vividion for $1.5bn in ‘arm’s length acquisition’

by

Bayer bolsters its drug discovery capabilities through the acquisition of Vividion, which it says will benefit from an arm’s length business model. The deal – which could be worth up to $2 billion – strengthens Bayer’s small molecule oncology and immunology targets through the addition of Vividion Therapeutics’ chemoproteomic technology. According to German pharma giant Bayer, the platform can recognize unidentified binding pockets on protein targets by screening chemical probes against the human proteome to establish selectivity. The platform is…

August 5, 2021